External broker reports(aggregated public sources), Ord Minnett

Ord Minnett

Ord Minnett is a leading Australian wealth management group, incorporating full-service stockbroking, financial planning and funds management. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>4DX’s 1H24 result was largely in-line with OMLe across key metrics (revenue, cash flows, balance sheet), noting the majority were pre-reported at the 2Q24 release (Jan-24).</li><li>The company’s underlying cost base was better than expected (opex -5% vs pcp, -14% vs OMLe), highlighting strong cost control despite significant commercialisation progress.</li><li>While recent Imbio wins are incrementally positive (Blackford deal, VA research study), the bigger 2H24 catalysts include a Philips reseller agreement, VA progress (2nd ATO, proof of concept trial) and expansion of the Australian installed base. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

4DX’s 1H24 result was largely in-line with OMLe across key metrics (revenue, cash flows, balance sheet), noting the majority were pre-reported at the 2Q24 release (Jan-24).The company’s underlying cost base was better than expected (opex -5% vs pcp, -14% vs OMLe), highlighting strong cost control despite significant commercialisation progress.While recent Imbio wins are incrementally positive (Blackford deal, VA research study), the bigger 2H24 catalysts include a Philips reseller agreement, VA progress (2nd ATO, proof of concept trial) and expansion of the Australian installed base. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

4Dmedical Limited - Significant Progress in 1H24

4DMedical

4Dmedical Limited - Significant Progress in 1H24